Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
41.01
+0.10 (+0.23%)
Streaming Delayed Price
Updated: 9:33 AM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gsk Plc ADR
< Previous
1
2
3
Next >
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
April 03, 2024
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia
Via
MarketBeat
Exposures
Product Safety
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer
March 16, 2024
From
GSK plc
Via
Business Wire
GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates Begin to Show Promising Rise
March 07, 2024
From
GSK plc
Via
Business Wire
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
February 08, 2024
The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally
From
Alector, Inc.
Via
GlobeNewswire
23andMe Reports Third Quarter Fiscal 2024 Financial Results
February 07, 2024
Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset 23ME-1473
From
23andMe, Inc.
Via
GlobeNewswire
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
February 07, 2024
From
Alector, Inc.
Via
GlobeNewswire
GSK’s RSV Vaccine, AREXVY, Accepted Under Priority Review in US for the Prevention of RSV Disease in Adults Aged 50-59 at Increased Risk
February 06, 2024
From
GSK plc
Via
Business Wire
Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA Production Technology
January 24, 2024
From
Elegen
Via
Business Wire
GSK Enters Agreement to Acquire Aiolos Bio
January 09, 2024
From
Aiolos Bio, Inc.
Via
Business Wire
GlaxoSmithKline PLC (NYSE: GSK) Records 52-Week High Monday Morning
January 08, 2024
Via
Investor Brand Network
GSK Awards $1M in COiMMUNITY Initiative Grants to Support Adult Immunization and Health Equity
December 12, 2023
From
GSK plc
Via
Business Wire
3 cheap 'stock'-ing stuffers Wall Street is bullish on
December 07, 2023
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
These biotechs targeting multiple neurodegenerative diseases
December 01, 2023
A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.
Via
MarketBeat
GSK and Queer Eye’s Thom Filicia Partner on Blood Cancer Awareness Initiative
November 13, 2023
From
GSK plc
Via
Business Wire
GSK is a remedy for the winter investment blahs
November 07, 2023
Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.
Via
MarketBeat
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
From
23andMe, Inc.
Via
GlobeNewswire
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
October 27, 2023
From
Alector, Inc.
Via
GlobeNewswire
New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
October 25, 2023
From
GSK plc
Via
Business Wire
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 27, 2023
By David Willey, Benzinga
Via
TheNewswire.com
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
September 15, 2023
From
GSK plc
Via
Business Wire
GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations
September 05, 2023
From
GSK plc
Via
Business Wire
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
From
GSK plc
Via
Business Wire
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
July 31, 2023
From
GSK plc
Via
Business Wire
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
July 13, 2023
From
GSK plc
Via
Business Wire
Drugmaker GSK: Becoming a Healthier Value Stock
June 27, 2023
Up more than 25% in the last nine months, U.K. pharmaceutical company GSK PLC is slowly regaining favor with investors after the GSK lawsuit.
Via
MarketBeat
Topics
Lawsuit
Exposures
Financial
Legal
US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices votes to recommend AREXVY for the prevention of RSV disease in adults aged 60 and older with shared clinical decision making
June 21, 2023
From
GSK plc
Via
Business Wire
GSK shares positive data for AREXVY, its respiratory syncytial virus (RSV) older adult vaccine, indicating protection over two RSV seasons
June 21, 2023
From
GSK plc
Via
Business Wire
GSK and Lifetime® Release Short Film Featuring Soleil Moon Frye and Melissa Joan Hart Urging Parents to “Ask2BSure” about Meningitis B
June 20, 2023
From
GSK plc
Via
Business Wire
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
GSK Announces the COiMMUNITY Initiative to Help Achieve Higher Adult Vaccination Rates in the US
June 01, 2023
From
GSK plc
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.